Research Fellow @FisherLabMGH, Harvard Medical School #Melanoma #Epigenetics #AdaptiveResistance
Boston, MA, USA
Joined January 2010
- Tweets97
- Following107
- Followers90
- Likes404
Pinned Tweet
It has been a fantastic last three years of my research career @CentenaryInst. I am really grateful to my mentors @Peter @JessTiffen, labmates and all other colleagues.
I am really excited and looking forward to the next phase of my research career @FisherLabMGH @harvardmed
Delighted to share our latest work which I co-lead with @JessTiffen. Epigenetic inhibitor against BET proteins and antiCTLA-4 synergistically reduce tumor growth which are resistance to anti-PD1. Hope it can make a meaningful impact in clinical settings. @DrHYTseng @JessTiffen.
More great work from my team on epigenetic BET inhibitors.
Here we show they combine well with antiCTLA-4 immune checkpoint inhibition (ICI) to combat melanoma with innate resistance to antiPD-1/L1 (frontline) ICI in a mouse model.
@DrHYTseng @emran_geb
onlinelibrary.wiley.com/doi/…
Great piece of work from my PhD Lab .
Yet another strong evidence of epigenetic reprogramming in adaptive resistance of multiple solid tumor models. Congrats to everyone involved in this fascinating project. Happy to be a part of it. @HelmutSchaider@DinoopMenon @Heinz @HaassLab
Hot off the press:
Drug Resist Updat, accepted 4th August 2023;
doi: doi.org/10.1016/j.drup.2023.…
Congrats to Helmut and his team and collaborators - fantastic work!
#FrazerInstUQ, @UQDRC, @UQMedicine, @TRI_info, @CUDenver, @UCSF, @otago, @JOAN_RESEARCH, @TheWistar,
Couldn't agree more! A must-read thread..
Happy to share our latest commentary article on
"Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma" based on a recent seminal work and our previous works. First from @FisherLabMGH
#Epigenetics #Melanoma
jidonline.org/article/S0022-…
Abdullah Al Emran retweeted
Prof Peter Hersey is generally recognised as a pioneer of the #melanoma treatment – #immunotherapy – in Australia. Having first started treating melanoma patients in 1980, he has seen great advances in field but he is not going to stop there.
More 👉 ow.ly/PtHe50GSVvV
"MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma," a commentary by Charles Adelmann, Inbal Rachmin, & David Fisher
bit.ly/3xLq5Zn #JIDJournal #dermscience
Congratulations Australia for winning the maiden T20 World cup title. What a team! What a match! Super proud of you guys...
Love and respect for New Zealand. Well played. In the end, cricket wins.
#T20WorldCupFinal
espncricinfo.com/series/icc-…
When you change a lab and start everything from the scratch...
#AcademicChatter #ResearchLife
Many thanks for promoting our work @CentenaryInst
LATEST NEWS: Researchers from the Centenary Institute have developed a new approach to fighting #melanomas that fail to respond – or are resistant – to standard treatments. More: centenary.org.au/cen_news/ne…
Delighted to share our latest findings- "Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor resistant melanoma"
Excellent work from @Farzana& @DrHYTseng.
My #2 as a co-senior author.
@CentenaryInst @Jess @Peter
jidonline.org/article/S0022-…
Couldn't agree more! Additionally, It should also be adjusted according to the living cost of some expensive states/cities. It's not a big ask and could be encouraging for the young scientist who wants to pursue their career in academia.
This Post is from an account that no longer exists. Learn more
Brilliant piece of work. A must-read for melanoma researchers.
Why do mutations only sometimes cause cancer? In our new @ScienceMagazine paper, we describe a mechanism for this called "oncogenic competence": science.org/doi/10.1126/scie…
Our new findings @biorxivpreprint
Happy to share our latest findings on repurposing the existing chemotherapy to induce innate inflammasomes for a potential therapeutic option of BRAF/MAPKi resistant melanoma. @Farzana @DrHYTseng @JessTiffen #PeterHersey @CentenaryInst
Repurposing melanoma chemotherapy to activate inflammasomes in treatment of BRAF/MAPK inhibitor-resistant melanoma biorxiv.org/cgi/content/shor… #bioRxiv
The age of epigenetic inhibitors is now and ahead for improving therapeutic efficacy in cancers. A comprehensive review on the role of histone demethylases(erasers) in melanoma other cancers from our lab. Nice work @Gaya19628293 @JessTiffen
Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers frontiersin.org/article/10.3… everything you need to know about lysine demethylases in cancer but didn’t know you needed to know. An excellent review from my PhD student @Gaya19628293 and @emran_geb
Our paper is out now in print @JIDJournals. Thanks again to all my colleagues and collaborator. Special thanks to my mentors @JessTiffen, Stuart and Peter. Such a lovely team to work with 🙏
sciencedirect.com/science/ar…
A fantastic achievement and thoroughly deserved. Many congrats @JessTiffen. Wishing you more success ahead. We are proud of you.
LATEST NEWS: The Centenary Institute's @JessTiffen has been awarded a grant from Cancer Council NSW to investigate a new approach to reverse treatment resistance in #melanoma. centenary.org.au/cen_news/bo… @CCNSWResearch
